Last reviewed · How we verify
JTE-451 Tablets
JTE-451 is a selective antagonist of the P2X7 receptor, which modulates immune cell activation and inflammatory responses.
JTE-451 is a selective antagonist of the P2X7 receptor, which modulates immune cell activation and inflammatory responses. Used for Inflammatory bowel disease, Rheumatoid arthritis.
At a glance
| Generic name | JTE-451 Tablets |
|---|---|
| Sponsor | Akros Pharma Inc. |
| Drug class | P2X7 receptor antagonist |
| Target | P2X7 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
P2X7 is an ATP-gated ion channel expressed on immune cells that plays a role in inflammasome activation and cytokine release. By blocking P2X7, JTE-451 reduces excessive immune activation and inflammatory signaling, potentially beneficial in inflammatory and autoimmune conditions. This mechanism targets the purinergic signaling pathway involved in innate immunity.
Approved indications
- Inflammatory bowel disease
- Rheumatoid arthritis
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (PHASE2)
- Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JTE-451 Tablets CI brief — competitive landscape report
- JTE-451 Tablets updates RSS · CI watch RSS
- Akros Pharma Inc. portfolio CI